AbbVie (NYSE: ABBV) reported Q1 EPS of $2.42, $0.17 better than the analyst estimate of $2.25. Revenue for the quarter came in at $8.62 billion versus the consensus estimate of $8.33 billion.

GUIDANCE:

AbbVie sees FY2020 EPS of $9.61-$9.71, versus the consensus of $9.48.

• AbbVie is updating its standalone GAAP diluted EPS guidance for the full-year 2020 from $7.66 to $7.76 to $7.60 to $7.70, representing growth of 44.9 percent at the midpoint. AbbVie is confirming the previous expectation to deliver standalone adjusted diluted EPS for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The company's standalone 2020 adjusted diluted EPS guidance excludes $2.01 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.